Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: Long-term results of a placebo-controlled randomised study

  • Karasawa K
  • Sunamura M
  • Okamoto A
 et al. 
  • 6


    Mendeley users who have this article in their library.
  • 27


    Citations of this article.


Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative radiotherapy. Short-term survival was not different. However, difference has been observed concerning 3-year survival (doranidazole group vs. placebo; 23% vs. 0%, p = 0.0192). This sensitiser might be effective in improving long-term survival for pancreatic cancer. © 2008 Elsevier Ireland Ltd. All rights reserved.

Author-supplied keywords

  • Doranidazole
  • Hypoxic cell radiosensitiser
  • IORT
  • Pancreatic cancer
  • Radiotherapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Katsuyuki Karasawa

  • Makoto Sunamura

  • Atsutake Okamoto

  • Kenji Nemoto

  • Seiki Matsuno

  • Yasumasa Nishimura

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free